Autopsy report · NCT03608618

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

“Sponsor shift in focus”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

MaxCyte, Inc.

Sponsor type

Industry

Conditions

Peritoneal Mesothelioma; Fallopian Tube Adenocarcinoma; Adenocarcinoma of the Ovary; Primary Peritoneal Carcinoma

Interventions

MCY-M11; Cyclophosphamide

Participants

14

Sites

4

Countries

United States

Trials that died the same way

• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
  “Sponsor change” (72% match in meaning)
• VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure
  “Change in Sponsor” (70% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (70% match in meaning)
• Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer
  “change of sponsor” (69% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.